Nausea, bloating, diarrhea, or constipation are common as your body adjusts
You do not apply directly
Tirzepatide targets both GIP and GLP-1 receptors, potentially offering greater efficacy in some contexts
Key Features & Benefits: Dual agonist peptide GLP-1 & GIP receptor activity for metabolic and appetite research Pre-filled 40mg research pen Delivers 2.5mg, 5mg, 7.5mg, and 10mg doses with click-based precision Multi-dose pen Approximately 1216 weeks supply depending on dosing schedule Ready-to-use No reconstitution required, minimizing preparation errors Switch from Mounjaro Continue existing doses without restarting or re-titration Lab-grade peptide quality High-purity formulation suitable for biotech, clinical, and academic R&D Dosing & Research Applications: The Tirzepatide 40mg pen supports weekly dosing at 2.5mg, 5mg, 7.5mg, and 10mg, making it ideal for researchers already established on Tirzepatide or Mounjaro protocols
No, our weight loss programs do not require insurance although if your insurance covers GLP medications, we can prescribe with insurance coverage
The World Health Organization suggests different BMI cutoffs for Asian and non-Asian populations: GLP-1 RAs are proven to effectively control blood sugar, making them a valuable option for many diabetes patients
